US2024676A - Production and concentration of an antithyroid component - Google Patents

Production and concentration of an antithyroid component Download PDF

Info

Publication number
US2024676A
US2024676A US615475A US61547532A US2024676A US 2024676 A US2024676 A US 2024676A US 615475 A US615475 A US 615475A US 61547532 A US61547532 A US 61547532A US 2024676 A US2024676 A US 2024676A
Authority
US
United States
Prior art keywords
antithyroid
component
blood
protein
precipitated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US615475A
Inventor
Blum Ferdinand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals Dresden
Original Assignee
Saechsisches Serumwerk Dresden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saechsisches Serumwerk Dresden filed Critical Saechsisches Serumwerk Dresden
Application granted granted Critical
Publication of US2024676A publication Critical patent/US2024676A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • A61K35/407Liver; Hepatocytes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/829Blood
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/838Marrow; spleen
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/843Digestive system
    • Y10S530/846Liver

Definitions

  • the antithyroid component is obtained from blood or organic tissue in so far as an antithyroid hormone is present or formed therein.
  • This antithyroid effect is not due to the physical adsorption of thyroid gland substanceby the blood and, further,-does not depend on the colloidal condition of the blood but must nent of the blood.
  • the antithyroid component which must be considered as counter-hormone can be best characterized biologically 20 by saying that it will counteract or reduce the such as thyreoglobulin, thyroxin or the like, on amphibia (precipitated metamorphosis and stunted growth).
  • the effects of certain amounts of thyroxin, for instance, whose converting power on tadpoles, for example, can be determined quantitatively, will be fully neutralized by accurately dosable amounts of the antithyroid component.
  • the administration of anti- 30 hormone (catechin) is indicated.
  • the employment of the antithyroid hormone has been found to be of particular therapeutic value to act as protective matter against the phenomena of enlarged delivery of iodine albumen from the thyroid gland to the blood, as in Morbus Basedow.
  • the invention discloses a method of obtaining from the initial materials highly purified antithyroid hormone, so that one need not be satisfled with giving, as a maximum, 50 to 100 cu. cms. blood, but is in a position to give the eifective substance of say 2 liters of blood, 1. e., twenty to forty times the amount mentioned, concentrated in the form of 1 to 2 grams.-
  • the initial material is blood or organic tissue which contains the antithyroid component in larger quantities, such as the liver and spleen, which are the organs where the blood is formed or converted.
  • the antithyroid hormone is only loosely combined with albumen and can be separated therefrom by coagulation.
  • the antithyroid hormone does not dialyze through a membrane.
  • the antithyroid component is obtained from the blood or its red corpuscles or the haemoglobin by separating the protein by coagulating agents.
  • the antithyroid component is thus freed from it's adherence to the protein and passes into the filtrate of the precipitation.
  • Further purification of the extract enriched by antithyroid hormone by freeing it from salts and dialyzable impurities can be efiected by dialysis which can be applied also to the initial materials.
  • Solvents such as acetone or alcohol which are miscible with water,
  • coagulants may serve as coagulants, though coagulation by heat, possibly with the addition of suitable salts, metallic salts, colloidal iron and the like, will also free the antithyroid component from its adherence to protein.
  • Example 1 One liter of blood or of disintegrated tissue of liver or spleen is placed in a multiple quantity of acetone or alcohol whereby the protein constituents will be coagulated. After the solution'has been allowed to stand for some time the coagulation is separated from the solution, the solvent carefully distilled ofi and any .ifi-tjthfit has separated removed. The aqueous and other dialyzable substances.
  • Additional quantities of effective antithyroid substances can be obtained from the coagulation by repeatedly treating the latter with one to two liters of cold or warm water or with aqueous alcohol or acetone. After separating the coagulation from the extract the solution is considerably concentrated. Dissolved protein can be precipitated with alcohol or acetone. The filtrate, on being freed from protein, is concentrated after driving out the solvent and can then be used.
  • Example 2.--Blo0d red corpuscles'or haemoglobin are treated with low concentrations of acids whereupon the acids in the mixture are saturated by alkalies and the neutral solution is concentrated.
  • the next step is to free this product from the protein by means of one of the coagulants stated, by adding for instance, alcohol, and
  • the first part may, by way of example, be carried out as follows: One liter blood possibly after drying, is treated with one to two liters of sulfuric acid. From the extract the'sulfuric acid is precipitated by barium compounds" and the largest share of dissolved albumen is precipitated also. The neutral solution is concentrated and the protein which is still in solution precipitated according to Example 1.
  • Example 3.0ne liter of blood that has been rendered non-coagul'able is dialyzed 24 hours, once or twice, against water to free it from salts This precleaned blood may then be treated in accordance with Examples 1 and 2. Dialysis may further take place at any step of the processes described .in Examples 1 and 2 for instance after precipitating the protein.
  • a method of obtaining an antithyroid concentrate which comprises treating a substance of the class consisting of blood, liver and spleen to precipitate protein therefrom, filtering the precipitated protein, repeatedly extracting the precipitated proteinous matter with water to produce an aqueous extract, concentrating the filtrate and the aqueous extract'derived from the precipitate, and thereafter dialyzing and evaporating the filtrate and aqueous extract to dryness if necessary.
  • a method of obtaining an antithyroidconcentrate which comprises treating a substance of the class consisting of blood, liver and spleen with organic solvents to precipitate protein therefrom, filtering the precipitated protein, repeatedly extracting the precipitated proteinous matter with water to produce a substantially aqueous extract, concentrating the filtrate and the aqueous extract derived from the precipitate, and thereafter dialyzing and evaporating the filtrate and aqueous extract to dryness if necessary.
  • a method of obtaining. an antithyroid concentrate which comprises treating a substance oi the class consisting of blood, liver and spleen with heat to precipitate protein therefrom, filtering the precipitated protein, repeatedly extracting the precipitated proteinous matter with water to produce a substantially aqueous extract, concentrating the-filtrate and the aqueous extract derived from the precipitate, and thereafter dialyzing and evaporating the filtrate and aqueous extract to dryness if necessary.
  • a method of obtaining an antithyroid concentrate which comprises treating a substance of the class consisting of blood, liver and spleen with heat and acids to precipitate protein therefrom, filtering the precipitated protein, repeatedly extracting the precipitated proteinous matter with water to produce an aqueous extract, dialyzing and concentrating the filtrate and the aqueous extract derived from the precipitate, and evaporating the filtrate and aqueous extract to dryness if necessary.

Description

Patented Dec. 17, 1935 PRODUCTION AND dONCENTRATION OF AN ANTITHYROID COMPONENT Ferdinand Blum, Frankfort-on-the-Main, Germany, assignor to Siichsisches Serumwerk Aktiengesellschaft, Dresden, Germany No Drawing. Application June 4, 1932, Serial No.
4 Claims.
This invention relates to a method of obtaining and concentrating an antithyroid component. According to the invention, the antithyroid component is obtained from blood or organic tissue in so far as an antithyroid hormone is present or formed therein. I have found by experiments that every blood as well as organs, such as the spleen and liver, contain an antithyroid component which has an important influence on the regulation of the action of the thyroid gland.. This antithyroid effect is not due to the physical adsorption of thyroid gland substanceby the blood and, further,-does not depend on the colloidal condition of the blood but must nent of the blood. The antithyroid component which must be considered as counter-hormone (catechin) can be best characterized biologically 20 by saying that it will counteract or reduce the such as thyreoglobulin, thyroxin or the like, on amphibia (precipitated metamorphosis and stunted growth). The effects of certain amounts of thyroxin, for instance, whose converting power on tadpoles, for example, can be determined quantitatively, will be fully neutralized by accurately dosable amounts of the antithyroid component. Wherever, abnormally, thyroid iodine substance appears, the administration of anti- 30 hormone (catechin) is indicated.
The employment of the antithyroid hormone has been found to be of particular therapeutic value to act as protective matter against the phenomena of enlarged delivery of iodine albumen from the thyroid gland to the blood, as in Morbus Basedow.
Therapeutic employment of the antithyroid component has hitherto been handicapped by the fact that excessive amounts of the material containing the component had to be taken to produce a curative effect. A successful and efiective therapy was therefore impossible and it was'necossary to originate a method of obtaining the antithyroid component from the initial material,
freed from all unnecessary ballast, and of enrlching it.
The invention discloses a method of obtaining from the initial materials highly purified antithyroid hormone, so that one need not be satisfled with giving, as a maximum, 50 to 100 cu. cms. blood, but is in a position to give the eifective substance of say 2 liters of blood, 1. e., twenty to forty times the amount mentioned, concentrated in the form of 1 to 2 grams.-
dv c bebe atartibuted to a certain hormone-like compovery marked eifect of thyroid gland preparations,
In Germany June 17, 1931 comes still more remarkable when it is taken into consideration that it is possible to inject, at the highest, only a few cubic centimeters of the difllcultly sterilizable blood and that by the use of the foreign albumen this process involves always, 5 and particularly during repetition, grave dangers while the invention makes it possible to repeatedly inject the efiective component obtained from 1 to 2 liters of blood without any fear of injurious consequences.
The initial material is blood or organic tissue which contains the antithyroid component in larger quantities, such as the liver and spleen, which are the organs where the blood is formed or converted.
It has been ascertained that the antithyroid hormone is only loosely combined with albumen and can be separated therefrom by coagulation.
It is further soluble in water and in aqueous organic solvents, i. e., solvents miscible with water. The antithyroid hormone does not dialyze through a membrane.
The antithyroid component is obtained from the blood or its red corpuscles or the haemoglobin by separating the protein by coagulating agents.
The antithyroid component is thus freed from it's adherence to the protein and passes into the filtrate of the precipitation. A large portion of the antithyroid component, during the coagulation of the protein, passes immediately into the solution and the residual portion is extracted from the coagulation to which it adheres now in the free state by means of water or organic solvents soluble in water. Further purification of the extract enriched by antithyroid hormone by freeing it from salts and dialyzable impurities can be efiected by dialysis which can be applied also to the initial materials. Solvents, such as acetone or alcohol which are miscible with water,
may serve as coagulants, though coagulation by heat, possibly with the addition of suitable salts, metallic salts, colloidal iron and the like, will also free the antithyroid component from its adherence to protein.
The method mentionedabove would be carried out as follows:
Example 1.One liter of blood or of disintegrated tissue of liver or spleen is placed in a multiple quantity of acetone or alcohol whereby the protein constituents will be coagulated. After the solution'has been allowed to stand for some time the coagulation is separated from the solution, the solvent carefully distilled ofi and any .ifi-tjthfit has separated removed. The aqueous and other dialyzable substances.
solution is then concentrated or possibly dried and is then ready for use.
Additional quantities of effective antithyroid substances can be obtained from the coagulation by repeatedly treating the latter with one to two liters of cold or warm water or with aqueous alcohol or acetone. After separating the coagulation from the extract the solution is considerably concentrated. Dissolved protein can be precipitated with alcohol or acetone. The filtrate, on being freed from protein, is concentrated after driving out the solvent and can then be used.
Example 2.--Blo0d, red corpuscles'or haemoglobin are treated with low concentrations of acids whereupon the acids in the mixture are saturated by alkalies and the neutral solution is concentrated. The next step is to free this product from the protein by means of one of the coagulants stated, by adding for instance, alcohol, and
ing solution.
While the second part of the method is carried out as described in Example 2, the first part may, by way of example, be carried out as follows: One liter blood possibly after drying, is treated with one to two liters of sulfuric acid. From the extract the'sulfuric acid is precipitated by barium compounds" and the largest share of dissolved albumen is precipitated also. The neutral solution is concentrated and the protein which is still in solution precipitated according to Example 1.
Example 3.0ne liter of blood that has been rendered non-coagul'able is dialyzed 24 hours, once or twice, against water to free it from salts This precleaned blood may then be treated in accordance with Examples 1 and 2. Dialysis may further take place at any step of the processes described .in Examples 1 and 2 for instance after precipitating the protein.
I claim:--
1. A method of obtaining an antithyroid concentrate which comprises treating a substance of the class consisting of blood, liver and spleen to precipitate protein therefrom, filtering the precipitated protein, repeatedly extracting the precipitated proteinous matter with water to produce an aqueous extract, concentrating the filtrate and the aqueous extract'derived from the precipitate, and thereafter dialyzing and evaporating the filtrate and aqueous extract to dryness if necessary.
2. A method of obtaining an antithyroidconcentrate which comprises treating a substance of the class consisting of blood, liver and spleen with organic solvents to precipitate protein therefrom, filtering the precipitated protein, repeatedly extracting the precipitated proteinous matter with water to produce a substantially aqueous extract, concentrating the filtrate and the aqueous extract derived from the precipitate, and thereafter dialyzing and evaporating the filtrate and aqueous extract to dryness if necessary.
3. A method of obtaining. an antithyroid concentrate which comprises treating a substance oi the class consisting of blood, liver and spleen with heat to precipitate protein therefrom, filtering the precipitated protein, repeatedly extracting the precipitated proteinous matter with water to produce a substantially aqueous extract, concentrating the-filtrate and the aqueous extract derived from the precipitate, and thereafter dialyzing and evaporating the filtrate and aqueous extract to dryness if necessary.
4. A method of obtaining an antithyroid concentrate which comprises treating a substance of the class consisting of blood, liver and spleen with heat and acids to precipitate protein therefrom, filtering the precipitated protein, repeatedly extracting the precipitated proteinous matter with water to produce an aqueous extract, dialyzing and concentrating the filtrate and the aqueous extract derived from the precipitate, and evaporating the filtrate and aqueous extract to dryness if necessary.
FERDINAND BLUM.
US615475A 1931-06-17 1932-06-04 Production and concentration of an antithyroid component Expired - Lifetime US2024676A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2024676X 1931-06-17

Publications (1)

Publication Number Publication Date
US2024676A true US2024676A (en) 1935-12-17

Family

ID=7978529

Family Applications (1)

Application Number Title Priority Date Filing Date
US615475A Expired - Lifetime US2024676A (en) 1931-06-17 1932-06-04 Production and concentration of an antithyroid component

Country Status (1)

Country Link
US (1) US2024676A (en)

Similar Documents

Publication Publication Date Title
DE2854381A1 (en) PROCESS FOR THE OBTAINMENT OF ANTIHAEMOPHILIC FACTOR VIII FROM BLOOD, BLOOD PLASMA OR BLOOD PLASMA FRACTIONS
DE2301501C3 (en) Process for obtaining a stable plasma protein free from hypotensive substances
LU83577A1 (en) METHOD FOR PRODUCING A HIGH FACTOR VIII (AHF) CONCENTRATE
DE2459915A1 (en) PLASMINOGEN TYPE COMPOUNDS AND METHOD OF PRODUCING THEREOF
US3461205A (en) Process of extracting proteins from potatoes
CH338273A (en) Process for the production of stable, highly purified γ-globulin preparations
US2024676A (en) Production and concentration of an antithyroid component
DE3101001A1 (en) METHOD FOR CONCENTRATING AND CLEANING THE ANTIHAEMOPHILIA FACTOR OR FACTOR VIII
DE2703620C2 (en) Process for the preparation of a concentrate of antihemophilia factor
EP0127025B1 (en) Process for preparing an antihaemophilic factor concentrate
DE3019895A1 (en) PLASMA EXPANDER
US2154934A (en) Purified bee poison
DE2720041A1 (en) HEART STRENGTHENING AGENT
US2143475A (en) Therapeutic agent
DE2409650C3 (en) Use of an aqueous solution of human serum haptoglobin in the fight against hemolytic kidney disorders
DE2855827A1 (en) PROCESS FOR THE PRODUCTION OF HUMAN CHORION SOMATOMAMMOTROPINE
DE2403065A1 (en) METHOD FOR PRODUCING THERAPEUTIC BLOOD FRACTIONS
US2256933A (en) Process for obtaining a substance lowering the blood pressure
US2099708A (en) Therapeutic product and method of making same
DE136103C (en)
McBride Taking the first steps in the development of peritoneal dialysis
DE576446C (en) Process for obtaining an inactivator of a bloodstream hormone
JPS60197627A (en) Healthy tea of kumis kuching
DE1818054C2 (en) Process for the production of cytobiotic globulins
DE487199C (en) Process for the preparation of purified tuberculin preparations